Research programme: peptides therapeutics - Interprotein/Ipsen
Latest Information Update: 30 Dec 2015
At a glance
- Originator Interprotein Corporation; Ipsen
- Class Peptides; Proteins
- Mechanism of Action Immunomodulators; Peptide modulators; Protein-protein interaction inhibitors; Protein-protein interaction modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Endocrine disorders